Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Leuprolide Acetate

FDA-approved product (solution, subcutaneous), marketed as Eligard Kit, Fensolvi Kit, Leuprolide Acetate and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Leuprolide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Central precocious puberty
  • Metastatic prostate cancer
  • Neoplasm
  • Precocious puberty
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Gonadotropin releasing hormone analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Leuprolide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Leuprolide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

    NCT03951831 · start 2019-05-16

    Registered record
    Registry ID
    NCT03951831
    Conditions
    Prostate Cancer Metastatic
    Interventions
    REGN2810; Degarelix; Leuprolide Acetate; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-05-16
    Completion
    2028-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionREGN2810; Degarelix; Leuprolide Acetate; Docetaxel
    PhasePhase 2
    Registry statusActive not recruiting

  • Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

    NCT03931915 · start 2019-05-08

    Registered record
    Registry ID
    NCT03931915
    Conditions
    Endometriosis
    Interventions
    TAK-385; Leuprorelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-05-08
    Completion
    2020-09-28
    Enrolment
    335

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionTAK-385; Leuprorelin acetate
    PhasePhase 3
    Registry statusCompleted

  • A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

    NCT03809000 · start 2019-04-15

    Registered record
    Registry ID
    NCT03809000
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-15
    Completion
    2029-09-15
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

    NCT03695237 · start 2018-10-24

    Registered record
    Registry ID
    NCT03695237
    Conditions
    Central Precocious Puberty (CPP)
    Interventions
    Leuprolide Acetate (LA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-24
    Completion
    2023-11-29
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty (CPP)
    InterventionLeuprolide Acetate (LA)
    PhasePhase 3
    Registry statusCompleted

  • A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

    NCT03311555 · start 2018-03-28

    Registered record
    Registry ID
    NCT03311555
    Conditions
    Prostate Cancer
    Interventions
    Apalutamide; Androgen deprivation; Salvage radiation therapy; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-28
    Completion
    2022-12-22
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionApalutamide; Androgen deprivation; Salvage radiation therapy; Docetaxel
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

    NCT05304169 · start 2017-11-14

    Registered record
    Registry ID
    NCT05304169
    Conditions
    Prostate Cancer
    Interventions
    Leuprorelin Acetate (Eligard® 45 mg).
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-11-14
    Completion
    2020-06-15
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprorelin Acetate (Eligard® 45 mg).
    PhasePhase 4
    Registry statusCompleted

  • A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

    NCT02993926 · start 2017-06-24

    Registered record
    Registry ID
    NCT02993926
    Conditions
    Central Precocious Puberty
    Interventions
    Enantone; GnRH agonist
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-06-24
    Completion
    2018-09-30
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty
    InterventionEnantone; GnRH agonist
    PhaseNot recorded
    Registry statusCompleted

  • Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate

    NCT02974270 · start 2016-06

    Registered record
    Registry ID
    NCT02974270
    Conditions
    Precocious Puberty, Central
    Interventions
    Leuprolide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-06
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrecocious Puberty, Central
    InterventionLeuprolide
    PhasePhase 4
    Registry statusUnknown

  • Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

    NCT03209492 · start 2016-04-01

    Registered record
    Registry ID
    NCT03209492
    Conditions
    Prostate Cancer
    Interventions
    Leuprorelin acetate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-04-01
    Completion
    2017-12-01
    Enrolment
    333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprorelin acetate
    PhaseNot recorded
    Registry statusCompleted

  • A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

    NCT02655237 · start 2016-03-05

    Registered record
    Registry ID
    NCT02655237
    Conditions
    Uterine Fibroids
    Interventions
    Relugolix; Relugolix Placebo; Leuprorelin; Leuprorelin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03-05
    Completion
    2017-09-25
    Enrolment
    281

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Fibroids
    InterventionRelugolix; Relugolix Placebo; Leuprorelin; Leuprorelin Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Medication Used to Stimulate Ovulation

    NCT02715336 · start 2015-10

    Registered record
    Registry ID
    NCT02715336
    Conditions
    IVF Cycle; Ovarian Stimulation; Egg Retrieval; Pregnancy; Miscarriages; Ovarian Hyperstimulation
    Interventions
    Ovulation induction with hCG and Lupron (GnRH agonist)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2021-09
    Enrolment
    666

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF Cycle; Ovarian Stimulation; Egg Retrieval; Pregnancy +2 more
    InterventionOvulation induction with hCG and Lupron (GnRH agonist)
    PhasePhase 4
    Registry statusUnknown

  • Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2

    NCT02229734 · start 2014-12

    Registered record
    Registry ID
    NCT02229734
    Conditions
    Prostate Cancer
    Interventions
    Radiation; Androgen Suppression
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-12
    Completion
    2021-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation; Androgen Suppression
    PhasePhase 2
    Registry statusCompleted

  • Markers of Pubertal Suppression During Therapy for Precocious Puberty

    NCT02006680 · start 2013-12

    Registered record
    Registry ID
    NCT02006680
    Conditions
    Central Precocious Puberty
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2013-12
    Completion
    2015-12
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

    NCT02064036 · start 2013-06-06

    Registered record
    Registry ID
    NCT02064036
    Conditions
    Adenocarcinoma of the Prostate
    Interventions
    Stereotactic Radiosurgical Boost; Casodex; Leuprolide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06-06
    Completion
    2021-10-29
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate
    InterventionStereotactic Radiosurgical Boost; Casodex; Leuprolide
    PhasePhase 1
    Registry statusCompleted

  • A Registry for Patients Treated on the Clinical Trial TAX 3503

    NCT01813370 · start 2013-03

    Registered record
    Registry ID
    NCT01813370
    Conditions
    Prostate Cancer
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-03
    Completion
    2022-03-04
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted